Form 4 for AMLX Amylyx Pharmaceuticals, Inc.
Accepted 2023-08-24 00:00:00 ET · period of report 2023-08-23 · accession 0000950170-23-044381 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-08-24 | 2023-08-23 | AMLX | FRATES JAMES M | CFO | M - OptEx | $6.88 | +18.2K | 106.3K | +21% | +$125.0K |
| D | 2023-08-24 | 2023-08-23 | AMLX | FRATES JAMES M | CFO | M - OptEx | $0.00 | -18.2K | 363.8K | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-23 | M | A | 18,165 | $6.88 | 106,341 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2023-08-23 | M | D | 18,165 | $0.00 | 363,835 | D | $6.88 · — to 2031-01-25 | 18,165 Common Stock | (F2) 113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter. |